Clinical Trials · NCT06254235
Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Enrollment
- 240
- Start date
- Jun 2021
- Locations
- 1 site, China
- Primary endpoint
- AUC0-28d